Compass Wealth Management LLC Acquires New Position in AbbVie Inc. $ABBV

Compass Wealth Management LLC purchased a new stake in shares of AbbVie Inc. ( NYSE:ABBV – Free Report ) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 25,828 shares of the company’s stock, valued at approximately $6,499,000. AbbVie makes up 1.2% of Compass Wealth Management LLC’s investment portfolio, making the stock its 25th biggest holding.

Other hedge funds and other institutional investors have also made changes to their positions in the company. ACT Advisors LLC. increased its position in shares of AbbVie by 2.5% in the 2nd quarter. ACT Advisors LLC. now owns 1,688 shares of the company's stock valued at $425,000 after acquiring an additional 41 shares during the period. Willner & Heller LLC lifted its position in AbbVie by 0.7% during the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company's stock worth $1,472,000 after acquiring an additional 43 shares during the period. B.O.S.S. Retirement Advisors LLC grew its stake in AbbVie by 3.1% during the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company's stock valued at $359,000 after purchasing an additional 43 shares during the last quarter. Fielder Capital Group LLC grew its stake in AbbVie by 1.7% during the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company's stock valued at $637,000 after purchasing an additional 43 shares during the last quarter. Finally, Leslie Global Wealth LLC increased its holdings in shares of AbbVie by 1.5% in the second quarter. Leslie Global Wealth LLC now owns 2,983 shares of the company's stock valued at $751,000 after purchasing an additional 44 shares during the period. Hedge funds and other institutional investors own 70.23% of the company's stock.

AbbVie Price Performance ABBV opened at $256.08 on Friday. The firm has a fifty day moving average price of $252.66 and a 200 day moving average price of $228.87. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $267.47. The stock has a market cap of $452.44 billion, a P/E ratio of 72.34, a P/E/G ratio of 0.85 and a beta of 0.30.

AbbVie ( NYSE:ABBV – Get Free Report ) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the prior year, the firm posted $2.97 earnings per share. The company's revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts expect that AbbVie Inc. will post 14.05 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie’s dividend payout ratio is currently 195.48%.

Positive Sentiment: Skyrizi regulatory expansion: AbbVie submitted an application to the European Medicines Agency for subcutaneous induction of Skyrizi in adults with moderately to severely active Crohn’s disease. If approved, the less invasive option could improve patient convenience, strengthen Skyrizi’s European franchise and support ...